<DOC>
	<DOCNO>NCT01739387</DOCNO>
	<brief_summary>This study compare patient handle Flutiform® pMDI ( pressurise meter dose inhaler ) breath activate device ( BAI ) . Patient handle assessed use assessment criterion detail correct handle step inhaler .</brief_summary>
	<brief_title>A Study Assessing Patient Handling Flutiform® Breath-Actuated Inhaler ( BAI ) Flutiform® Pressurised Metered Dose Inhaler ( pMDI )</brief_title>
	<detailed_description>Approximately 340 subject age 12 year asthma chronic obstructive pulmonary disease ( COPD ) , medication condition recruit study . Subjects recruited ensure different severity disease include study . Severity disease determine predict FEV1 . During study subject train use pMDI device BAI device compare . Following train subject ' use device assess trainer/assessor use assessment criterion cover handling , actuation inhalation aspect device test . The order subject receive device determine use randomisation schedule . During study subject continue take prescribed asthma COPD medication . The pMDI BAI device use patient handle assessment contain placebo . The duration study subject 58 day . Training use device separate 7 21 day</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Written inform consent/assent . 2 . Male female subject ≥12 year old . 3 . Documented history asthma COPD ≥ 6 month prior screen visit . 4 . Subjects receive ICS LABA 5 . Can perform spirometry adequately . 6 . Willing able attend study visit 1 . Any severe chronic respiratory disease asthma COPD . 2 . Evidence clinically unstable disease determine medical history physical examination , Investigator 's opinion , precludes entry study may confound betweenperiod comparison . 'Clinically unstable ' defined disease , opinion Investigator , would put Subject risk study participation . 3 . Any serious neuromuscular disorder , orofacial disease prevent application inhaler mouth . 4 . Known sensitivity inhaler propellant excipients . 5 . Participation clinical drug study within 30 day screen visit . 6 . Current participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Flutiform®</keyword>
	<keyword>Asthma</keyword>
	<keyword>COPD</keyword>
</DOC>